Waystar Holding Corp. Annual Report - Investor Summary

This summary offers a clear, actionable overview of Waystar Holding Corp.'s performance and strategic direction, drawn from its latest annual report. We aim to provide retail investors with key insights into the company's financial health, operational achievements, and future prospects.

---

Waystar Holding Corp. - Your Investor's Guide

1. Business Overview

Waystar Holding Corp. leads the healthcare payments software market, specializing in revenue cycle management (RCM) solutions. These solutions simplify and unify the healthcare payments process for providers, empowering them to optimize financial performance through innovative technology.

The year 2025 proved transformative, marked by significant strategic expansion and financial activities. A major milestone was Waystar's Initial Public Offering (IPO) in June 2024, which successfully transitioned the company to a public entity and raised substantial capital. Growth through acquisition remained a core strategy. In October 2025, Waystar acquired Iodine Software, a company specializing in AI-powered clinical documentation improvement (CDI) and revenue integrity solutions. This acquisition significantly enhances Waystar's RCM offerings by integrating advanced AI capabilities. This strategic move followed earlier acquisitions in 2023 of HealthPay24 (a patient payment platform) and Olive AI Inc.'s RCM division, consistently expanding Waystar's market reach and technological capabilities.

Waystar operates within a dynamic market shaped by several key trends and regulatory shifts:

• Digital Transformation in Healthcare: The industry rapidly adopts digital and cloud-based solutions, directly benefiting Waystar's core offerings.
• Rise of AI and Automation: Increasing demand for AI and machine learning streamlines administrative tasks, improves accuracy, and reduces costs in healthcare payments—a trend Waystar actively embraces through acquisitions like Iodine.
• Shift to Value-Based Care: As healthcare models move towards value-based care, providers require more sophisticated RCM tools to track outcomes and manage complex reimbursement structures, creating opportunities for Waystar.
• Increasing Regulatory Complexity: Ongoing changes in healthcare legislation, data privacy laws (e.g., HIPAA, state-specific regulations), and evolving payer requirements necessitate robust and adaptable RCM solutions. Waystar must continuously update its platform to ensure compliance and help clients navigate these complexities.
• Consolidation in Healthcare: Mergers and acquisitions among healthcare providers create larger clients with more complex RCM needs, but also potentially fewer, larger clients to serve.

2. Financial Performance

Waystar delivered robust financial performance in 2025. The company reported total revenue of approximately $1.2 billion, a strong 22% increase over 2024. Both organic growth in its core RCM platform and the successful integration of recent acquisitions drove this increase. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached $400 million, up 28% year-over-year, reflecting improved operational leverage and cost efficiencies.

Net income for 2025 was $150 million, a 10% increase from the prior year, even with increased investment in technology and acquisition-related integration costs. The company generated $250 million in operating cash flow, highlighting its strong ability to convert revenue into cash, crucial for debt management and future investments. These figures underscore Waystar's capacity for profitable growth while expanding its market footprint.

3. Risk Factors

Investors should be aware of several key risks that could impact Waystar's financial performance and stock price:

• Integration Risk: Waystar's growth strategy heavily relies on its ability to effectively integrate acquired businesses, such as Iodine, HealthPay24, and Olive AI's RCM division. Failure to achieve expected synergies or manage operational complexities could impact financial performance.
• Market Competition: The healthcare technology and RCM markets are highly competitive and rapidly evolving. New entrants, technological advancements by competitors, or pricing pressures could erode Waystar's market share or profitability.
• Regulatory Changes: Extensive and evolving healthcare regulations (e.g., HIPAA, changes in reimbursement models) govern the industry. Adverse regulatory changes could increase compliance costs, limit service offerings, or impact revenue.
• Cybersecurity and Data Privacy: Handling sensitive patient and financial data exposes Waystar to significant cybersecurity risks. Data breaches or failures in data protection could lead to reputational damage, legal liabilities, and financial losses.
• Economic Downturns: A broader economic downturn could reduce healthcare spending, impacting Waystar's client base and revenue streams.
• Secondary Offerings: Institutional investors conducted several secondary offerings throughout 2025 (in February, May, and September), selling portions of their shares. Future secondary offerings by large institutional investors could create additional selling pressure on the stock, potentially leading to price volatility.

4. Management's Discussion and Analysis (MD&A) Highlights

Management's Discussion and Analysis highlights the company's operational results, financial condition, and strategic initiatives. The year 2025 proved transformative, beginning with the successful Initial Public Offering (IPO) in June 2024. This IPO provided significant capital for growth and enhanced Waystar's market visibility and credibility. The transition to a public entity also led to establishing new equity incentive plans in 2024, including stock options, restricted stock units (RSUs), performance shares, and an Employee Stock Purchase Plan (ESPP), all designed to align employee interests directly with shareholder value.

Key operational achievements included robust financial performance, with strong double-digit growth in revenue and Adjusted EBITDA. This demonstrated effective execution of growth strategies and operational efficiency. Strategic acquisitions, such as Iodine Software in October 2025, and earlier acquisitions of HealthPay24 and Olive AI's RCM division, were pivotal. They expanded Waystar's technological capabilities and market share, particularly in AI-driven solutions. These acquisitions are central to the company's strategy of diversifying its service offerings and increasing its competitive advantage.

However, management also navigated challenges, including the impact of multiple secondary offerings by institutional investors in 2025, which created periods of increased selling pressure on the stock. Successfully integrating acquired companies like Iodine, HealthPay24, and Olive AI's RCM division presents operational and cultural complexities. Management must carefully handle these to realize expected synergies. The company also operates within a highly competitive healthcare technology sector, requiring continuous innovation and investment to maintain market leadership. Management's strategy continues to focus on leveraging market trends such as digital transformation, the rise of AI, and the shift to value-based care to drive future growth.

5. Financial Health

Waystar actively manages a sophisticated capital structure to support its growth initiatives. The company maintains various debt arrangements, including a First Lien Term Loan Facility of approximately $2.5 billion (a primary, secured loan), a Revolving Credit Facility with $300 million available (a flexible line of credit), and a Receivables Facility (financing based on accounts receivable). In 2024 and 2025, Waystar engaged in several debt management activities, including refinancing existing debt for more favorable terms, repricing efforts to reduce interest costs, and strategic paydowns.

To mitigate financial risks, Waystar utilizes interest rate swaps. These financial agreements exchange interest payments, acting as hedges against potential increases in variable interest rates on its debt. This proactive approach helps stabilize borrowing costs and provides greater predictability in financial planning. As of year-end 2025, the company reported cash and cash equivalents of $180 million, coupled with significant available liquidity from its revolving credit facility. This indicates a healthy financial position to fund operations and future growth.

6. Future Outlook

Waystar's future outlook remains positive, driven by its strategic acquisitions and continued innovation. The integration of Iodine Software is expected to unlock new growth avenues in AI-driven clinical documentation and revenue integrity. Management anticipates continued double-digit revenue growth for 2026, fueled by market expansion, product innovation, and cross-selling opportunities within its expanded client base.

The company plans to further invest in research and development, particularly in artificial intelligence and automation, to enhance its platform's capabilities and maintain its competitive edge. Waystar is well-positioned to capitalize on the ongoing digital transformation within the healthcare industry and the increasing demand for efficient revenue cycle management solutions. The company continues to strengthen its executive leadership and board of directors to navigate the complexities of public company operations and sustain its growth trajectory.

7. Competitive Position

Waystar maintains a strong competitive position by leveraging its comprehensive, cloud-based RCM platform, which integrates seamlessly across the healthcare payments ecosystem. Its strategy of strategic acquisitions, exemplified by Iodine Software, HealthPay24, and Olive AI's RCM division, is crucial for expanding its technological capabilities, diversifying its service offerings, and increasing its market share.

The company differentiates itself through its AI-powered solutions, deep industry expertise, and a focus on delivering tangible value to healthcare providers. It achieves this by simplifying complex payment processes, reducing administrative burden, and improving financial outcomes. This allows Waystar to compete effectively against both niche RCM providers and larger enterprise software companies, by offering a unified and intelligent platform that addresses the evolving needs of the healthcare industry.